Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced ...
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a case-based session ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback